Arthritis Consumer Experts (ACE) has been sharing research-based information and education on biosimilars since 2009. ACE’s biosimilars work has centred on a national dialogue with people with arthritis, health care professionals and policy makers in government and private health insurance.
Biosimilar biologics are the next generation of originator biologic medications when they go off patent. They are safe, effective and highly cost effective, and give public and private insurers the ability to streamline special access criteria and hopefully, provide greater reimbursement coverage to more patients who need it. Below are some education videos on biosimilar biologics:
- Special video education series of JointHealth™ Education – ACE speaks to medical experts on key patient questions around transitioning between similar biologic medications
Special video education series of JointHealth™ Education
Special video education series of JointHealth™ Education

Arthritis Consumer Experts
© 2000-2023

ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealthTM information and programs.

Arthritis Consumer Experts
© 2000-2021

ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealthTM information and programs.


Arthritis Consumer Experts
© 2000-2021

ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealthTM information and programs.
